Effect of SMS 201-995 on exocrine pancreatic secretion in a patient with external pancreatic fistula
Tóm tắt
The effect of SMS 201-995 on pancreatic exocrine function was studied. The SMS 201-995 was adminis-tered to a patient with an artificial external pancreatic fistula following pancreaticoduodenectomy. Varia-tions in pancreatic exocrine function were assessed by determining the volume and components of the fistula fluid during the following periods: 5 d prior to SMS 201-995 administration, for 5 d during actual administration, and for 5 d after it had been discontinued. The SMS 201-995 was administered by subcu-taneous injection of 100 μg every 12 h for the first 2 d and then 100 μg every 6 h for 3 d. This experiment demonstrated that SMS 201-995 has a strong inhibitory effect on pancreatic exocrine function, markedly reducing the amount of fistula fluid and the production of amylase, total protein, and bicarbonate.
Tài liệu tham khảo
1Ohta T, Nagakawa T, Koyasaki N, Kadoya N, Mori K, Nakano T, Ueno K, Miyazaki I. A new management for the complete disruption of the pancreatojejunostomy following pancreatoduodenectomy.Jpn J Bil Pane 1991; 12: 595–599.
2Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J. A very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci 1982; 31: 1133–1140.
3Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somotostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.Digestion 1987; 36: 108–124.
4 Misumi A, Shiratori K, Lee KY, Barkin JS, Chey WY. Effects of SMS 201-995, a somatostatin analogue, on the exocrine pancreatic secretion and gut hormone release in dogs.Surgery 1988; 103: 450–455.
5Heij HA, Bruining HA, Verschoor L. A comparison of the effects of two somatostatin analogues in a patient with an external pancreatic fistula.Pancreas 1986; 1: 188–190.
6Domschke S. Domschke W, Rosch W, Konturek SJ, Sprugel W, Mitznegg P, Wunsch E, Demling L. Inhibition by somatostatin of secretin-stimulated pancreatic secretion in man: A study with pure pancreatic juice.Scand J Gastroenterol 1977; 12: 59–63.
7Williams ST, Woltering EA, O’Dorisio TM, Fletcher WS. Effect of octreotide acetate on pancreatic exocrine function.Am J Surg 1989; 157: 459–462.
Nagakawa T. Improvement technique for pancreatico- jejunostomy after extended pancreaticoduodenectomy.J Jpn Soc Clin Surg 1983; 44: 1000–1003.
Guillemin R, Burgus R. The hormones of hypothalamus.Sci Amer 1972; 227: 24.
Brazeau P, Vale V, Burgus R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.Science 1973; 179: 77–79.
Arimura A, Sato H, Dupont A. Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas.Science 1975; 189: 1007,1008.
Lins PE, Efendic S, Hall R. Effect of 24-hours somatostatin infusion on glucose homeostasis and on levels of somatostatin, pancreatic and thyroid hormones in man.Acta Med Scand 1979; 206: 441–445.
Bloom SR, Mortimer CH, Thorner MO. Inhibition of gastrin and gastric acid secretion by growth hormone releasing- inhibiting hormone (GH-RIH).Lancet 1974; 2: 1106–1109.
Boden G, Sivitz MC, Owen OE, Essa-Koumav N, Landon JH. Somatostatin supresses secretin and pancreatic exocrine secretion.Science 1975; 160: 163–165.
Thor P, Krol R, Konturek SJ, Coy DH, Schally AV. Effect of somatostatin on myoelectrical activity of small bowel.Am J Physiol 1978; 235: E249-E254.
Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.Gastroenterology 1981; 80: 518–525.
Mulvihill S, Pappas TN, Passaro E, Debas HT. The use of somatostatin and its analogues in the treatment of surgical disorders.Surgery 1986; 100: 467–476.
Nubiola P, Badia JM, Martinez RF. Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995.Ann Surg 1989; 210: 56–58.
Wood SM, Kraenzlin ME, Adrian TE, Bloom SR. Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue.Gut 1985; 26: 438–444.
Seino Y, Nakagawa S, Gotoh Y, Himizu N, Takada R, Saitoh S, Ibayashi H, Imura H. Multicenter clinical trial of SMS 201-995 in gastroenteropancreatic endocrine tumors.Jpn J Hormone and Clinics 1988; 36: 581–590.
Shiratori K, Watanabe S, Takeuchi T, Shimizu K, Moriyoshi Y, Cyoh K. Effects of SMS 201-995, long-acting somatostatin analogue, on the exocrine pancreatic secretion and gut hormone release in rats.J Jpn Pan Soc 1990; 5: 227.